Analytical Advances in the Ex Vivo Challenge Efficacy Assay-Reference-Cited by-同舟云学术

Analytical Advances in the Ex Vivo Challenge Efficacy Assay

Published:2017-04 Issue:4 Volume:33 Page:395-403
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Richardson-Harman Nicola¹,Parody Robert¹²,Anton Peter³,McGowan Ian⁴⁵,Doncel Gustavo⁶,Thurman Andrea Ries⁶,Herrera Carolina⁷,Kordy Kattayoun⁸,Fox Julie⁹,Tanner Karen³,Swartz Glenn¹⁰,Dezzutti Charlene S.⁴⁵

Affiliation:

1. Alpha StatConsult, LLC, Damascus, Maryland.

2. School of Mathematical Sciences, Rochester Institute of Technology, Rochester, New York.

3. Department of Medicine, David Geffen School of Medicine at UCLA, Center for HIV Prevention Research, UCLA AIDS Institute, Los Angeles, California.

4. School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.

5. Magee Womens Research Institute, Pittsburgh, Pennsylvania.

6. CONRAD, Eastern Virginia Medical School, Norfolk and Arlington, Virginia.

7. Division of Infectious Diseases, Faculty of Medicine, Imperial College, London, United Kingdom.

8. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, University of Southern California, Los Angeles, California.

9. Guys and St. Thomas' NHS Foundation Trust, London, United Kingdom.

10. Advanced Bioscience Laboratories, Gaithersburg, Maryland.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Virology,Immunology

Link

http://www.liebertpub.com/doi/pdf/10.1089/aid.2016.0073

Reference42 articles.

1. Correlation between Compartmental Tenofovir Concentrations and an Ex Vivo Rectal Biopsy Model of Tissue Infectibility in the RMP-02/MTN-006 Phase 1 Study

2. Dose-Response Relationship Between Tissue Concentrations of UC781 and Explant Infectibility with HIV Type 1 in the RMP-01 Rectal Safety Study

3. First Phase 1 Double-Blind, Placebo-Controlled, Randomized Rectal Microbicide Trial Using UC781 Gel with a Novel Index of Ex Vivo Efficacy

4. A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study)

5. Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study;PLOS ONE;2022-10-10

2. Ex Vivo HIV Infection Model of Cervico-Vaginal and Rectal Tissue;Methods in Molecular Biology;2022

3. An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate;AIDS Research and Human Retroviruses;2021-10-29

4. A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study);AIDS Research and Human Retroviruses;2021-09-14

5. Combined HIV Adolescent Prevention Study (CHAPS): comparison of HIV pre-exposure prophylaxis regimens for adolescents in sub-Saharan Africa—study protocol for a mixed-methods study including a randomised controlled trial;Trials;2020-10-30